Àΰ£ À¶¸ð¼º °í³ªµµÆ®·ÎÇÉ(hCG) ½ÃÀå : ±â¼úº°, Ä¡·á ¿µ¿ªº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2023-2030³â)
Human Chorionic Gonadotropin (hCG) Market with COVID-19 Impact Analysis by Technology, Therapeutic Area, End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
»óǰÄÚµå : 1400997
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2023³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 288 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,612,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,598,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,017,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸®Æ÷Æ® ÇÏÀ̶óÀÌÆ®

Àΰ£ À¶¸ð¼º °í³ªµµÆ®·ÎÇÉ(hCG) ½ÃÀå ±Ô¸ð´Â 2022³â¿¡ 7¾ï 1,087¸¸ ´Þ·¯¸¦ ±â·ÏÇßÀ¸¸ç, 2023-2030³â CAGR 6.48%·Î È®´ë

Àΰ£ À¶¸ð¼º ¼º¼±ÀÚ±ØÈ£¸£¸ó(hCG) ½ÃÀå - ½ÃÀå ¿ªÇÐ

ºÒÀÓ°ú ¼º±â´É ÀúÇÏÁõÀÇ À¯º´·ü Áõ°¡, »ýȰ½À°üÀÇ º¯È­, ºÒÀÓ Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.

ºÒÀÓ°ú ¼º¼±±â´ÉÀúÇÏÁõÀÇ À¯º´·ü Áõ°¡, »ýȰ½À°üÀÇ º¯È­, ºÒÀÓ Ä¡·á¿¡ ´ëÇÑ Áö½ÄÀÇ Çâ»ó µîÀÌ Àΰ£ À¶¸ð¼º ¼º¼±ÀÚ±ØÈ£¸£¸ó(HCG) »ê¾÷ÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¼º¼±±â´ÉÀúÇÏÁõÀº Ç÷û³» È£¸£¸óÀÎ Å×½ºÅ佺Å×·Ð ³óµµ°¡ ³·Àº °ÍÀ¸·Î Á¤ÀǵǸç, ¾ÆÄ§ ¹ß±â·Â ÀúÇÏ, ¹ß±âºÎÀü, ±â¾ï·Â ÀúÇÏ, ¼º¿å °¨Åð, °Ç°­ ¹× ü·Â ÀúÇÏ, ÁýÁß·Â ÀúÇÏ, ¿ì¿ïÁõ µî ´Ù¾çÇÑ ÀÓ»óÀû Ư¡À» º¸ÀÔ´Ï´Ù.2021³â7¿ùBMC Endocrine Disorders¿¡¼­ ¹ßÇ¥ÇÑ ¿¬±¸¿¡ µû¸£¸é ¹ß±âºÎÀüÀº 2021³â ¼¼°è ¼ºÀÎÀÇ 72.2%¿¡ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ̶ó°í ÇÕ´Ï´Ù.

Àΰ£ À¶¸ð¼º ¼º¼±ÀÚ±ØÈ£¸£¸ó(hCG) ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

AnalystView Market InsightsÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®µéÀÌ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é ¼¼°è Àΰ£ À¶¸ð¼º ¼º¼±ÀÚ±ØÈ£¸£¸ó(hCG) ½ÃÀåÀº ¿¹Ãø ±â°£(2023-2030³â) µ¿¾È ¸Å³â ¾à 6.48%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àΰ£ À¶¸ð¼º ¼º¼±ÀÚ±ØÈ£¸£¸ó(hCG) »ê¾÷Àº ºÒÀÓ ¹× ¼º¼±±â´ÉÀúÇÏÁõ À¯º´·ü Áõ°¡, »ýȰ½À°ü º¯È­, ºÒÀÓ Ä¡·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡·Î ÀÎÇØ ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±â¼ú ¼¼ºÐÈ­¿¡ ±â¹ÝÇϸé õ¿¬ÀÚ¿ø ÃßÃâÀº 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ä¡·á ºÐ¾ßº°·Î´Â ¿©¼º ºÒÀÓ Ä¡·á°¡ 2022³â ÁÖ¿ä ±â¼ú·Î ²ÅÇû½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î´Â ºÒÀÓ Ä¡·á Ŭ¸®´ÐÀÌ 2022³â ÁÖ¿ä ±â¼ú·Î ²ÅÇû½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2022³â ÁÖ¿ä ¼öÀÔ¿øÀ¸·Î ²ÅÇû½À´Ï´Ù.

Àΰ£ À¶¸ð¼º ¼º¼±ÀÚ±ØÈ£¸£¸ó(hCG) ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

Àΰ£ À¶¸ð¼º ¼º¼±ÀÚ±ØÈ£¸£¸ó(hCG) ¼¼°è ½ÃÀåÀº ±â¼ú, Ä¡·á ¿µ¿ª, ÃÖÁ¾»ç¿ëÀÚ ¹× Áö¿ªÀ» ±âÁØÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Á¦Ç° ±â¼ú¿¡ µû¶ó ÀçÁ¶ÇÕ ±â¼ú ¹× õ¿¬ À¯·¡ ÃßÃâ·Î ±¸ºÐµË´Ï´Ù. õ¿¬ À¯·¡ ÃßÃ⠺ι®Àº ¼¼°è ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ Áß¿¡µµ ±×·² °¡´É¼ºÀÌ ³ô½À´Ï´Ù. hCG ºÐ¾ßÀÇ ÁÖ¿ä °æÀï»çµéÀº õ¿¬ À¯·¡ ¼º¼±ÀÚ±ØÈ£¸£¸ó¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä¸¦ °¡Áö°í ÀÖÀ¸¸ç, ÀÌ´Â Áö³­ ¼ö³â°£ ½ÃÀåÀÇ Áß¿äÇÑ °³Ã´À̸ç, ÀÌ ºÐ¾ß°¡ ¹ú¾îµéÀÌ´Â ¸ÅÃâ¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº Ä¡·á ¿µ¿ª¿¡ µû¶ó ³²¼º ¼º¼±±â´ÉÀúÇÏÁõ, ¿©¼º ºÒÀÓ Ä¡·á, ÀúÁ¤ÀÚÁõ Ä¡·á ¹× ±âŸ·Î ºÐ·ùµË´Ï´Ù. ºÒÀÓÀº ºÎºÎ°¡ ÀÓ½ÅÀ» ÇÒ ¼ö ¾ø°Å³ª ¿©¼ºÀÌ ÀÓ½ÅÀ» Áö¼ÓÇÒ ¼ö ¾ø´Â »óŸ¦ ¸»ÇÕ´Ï´Ù. Àΰ£ À¶¸ð¼º ¼º¼±ÀÚ±ØÈ£¸£¸ó(HCG) È£¸£¸óÀº ÀӽŠÁß ¹è¾Æ ¹ß´Þ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ ºÒÀÓ Ä¡·á¿¡¼­ HCG¸¦ »ç¿ëÇÏ´Â °ÍÀº ³²³à ¸ðµÎ¿¡°Ô ÀαⰡ ÀÖ½À´Ï´Ù. ¿©¼º ºÒÀÓÀÇ ¿øÀÎÀº ´Ù¾çÇÕ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é Àڱà Áúȯ, ³­°ü ¸·Èû, ³­Æ÷ ¹®Á¦, ´Ù³¶¼º ³­¼Ò ÁõÈıº(PCOS), ´Ù¾çÇÑ ³»ºÐºñ°è Áúȯ°ú °°Àº ³­°ü ÀÌ»óÀÌ ÁÖ¿ä ¿øÀÎÀ¸·Î ²ÅÈü´Ï´Ù.

Àΰ£ À¶¸ð¼º ¼º¼±ÀÚ±ØÈ£¸£¸ó(hCG) ½ÃÀå - Áö¿ªÀû ÀλçÀÌÆ®

Áö¿ªÀûÀ¸·Î ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ ºÐÆ÷µÇ¾î ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ºñÁî´Ï½º¸¦ °¡Á® ¿À´Â ±¹°¡º°·Î ´õ ¼¼ºÐÈ­µË´Ï´Ù. ¿¹Ãø ±â°£ Áß ºÏ¹Ì´Â »ó´çÇÑ ½ÃÀå ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Áõ°¡´Â ÀÌ Áö¿ªÀÇ Àß ±¸ÃàµÈ ÀÇ·á ÀÎÇÁ¶ó, À¯¸®ÇÑ »óȯ ±ÔÁ¤, ºÒÀÓ¿¡ ´ëÇÑ ºÎ´ã Áõ°¡¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù.

Àΰ£ À¶¸ð¼º »ý½Ä»ùÀÚ±ØÈ£¸£¸ó(hCG) ½ÃÀå - °æÀï »óȲ :

±â¾÷Àº ±â¾÷ À¥»çÀÌÆ®, E-Commerce À¥»çÀÌÆ®, ¼Ò¸Å¾÷ü, À¯Åë¾÷ü, ÃÖÁ¾ ¼ÒºñÀÚ µî ´Ù¾çÇÑ Ã¤³ÎÀ» ÅëÇØ Á¦Ç°À» ÆÇ¸ÅÇÕ´Ï´Ù. ±â¾÷ÀÌ µµ´Þ ¹üÀ§¸¦ °­È­ÇÏ°í ½ÃÀå Á¡À¯À²À» È®´ëÇϱâ À§ÇØ »ç¿ëÇÏ´Â ÁÖ¿ä ¹æ¹ý¿¡´Â ½ÅÁ¦Ç° Ãâ½Ã, À¯Åë¸Á °³Ã´, R&D ºñ¿ë, M&A µîÀÌ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 6¿ù, ÀÎÆ®·ÎµàÄÉÀÌ¼Ç ÆÛ½Ç¸®Æ¼´Â ºÒÀÓ Ä¡·á Àü¹®°¡¿Í ȯÀÚ¿¡°Ô µ¶º¸ÀûÀÎ °æÇèÀ» Á¦°øÇÏ´Â Àå±â »ýü Á¶Á÷ ¹× ³Ãµ¿ º¸Á¸ ¼Ö·ç¼ÇÀÎ HavenCryo¸¦ ¹ßÇ¥ÇÏ¸ç »ýŰ踦 È®ÀåÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Àΰ£ À¶¸ð¼º °í³ªµµÆ®·ÎÇÉ(hCG) ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Àΰ£ À¶¸ð¼º °í³ªµµÆ®·ÎÇÉ(hCG)ÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå Àΰ£ À¶¸ð¼º °í³ªµµÆ®·ÎÇÉ(hCG) »ê¾÷ Á¶»ç

Á¦5Àå Àΰ£ À¶¸ð¼º °í³ªµµÆ®·ÎÇÉ(hCG) ½ÃÀå : COVID-19 °¨¿°ÁõÀÇ ¿µÇ⠺м®

Á¦6Àå Àΰ£ À¶¸ð¼º °í³ªµµÆ®·ÎÇÉ(hCG) ½ÃÀå ±¸µµ

Á¦7Àå Àΰ£ À¶¸ð¼º °í³ªµµÆ®·ÎÇÉ(hCG) ½ÃÀå - ±â¼úº°

Á¦8Àå Àΰ£ À¶¸ð¼º °í³ªµµÆ®·ÎÇÉ(hCG) ½ÃÀå - Ä¡·á ¿µ¿ªº°

Á¦9Àå Àΰ£ À¶¸ð¼º °í³ªµµÆ®·ÎÇÉ(hCG) ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå Àΰ£ À¶¸ð¼º °í³ªµµÆ®·ÎÇÉ(hCG) ½ÃÀå - Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - Àΰ£ À¶¸ð¼º °í³ªµµÆ®·ÎÇÉ(hCG) »ê¾÷

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Human Chorionic Gonadotropin (hCG) Market size was valued at USD 710.87 Million in 2022, expanding at a CAGR of 6.48% from 2023 to 2030.

Human Chorionic Gonadotropin (hCG) is a hormone generated by the placenta during pregnancy. It aids pregnancy by activating the corpus luteum in the ovaries to generate progesterone, which maintains the uterine lining and helps the growing fetus. hCG is also the hormone discovered in pregnancy tests since its levels grow considerably early in pregnancy. In addition to its role in reproduction, hCG has therapeutic applications, including as in fertility therapies and as a marker for various medical disorders, including several cancer technologies.

Human Chorionic Gonadotropin (hCG) Market- Market Dynamics

Increasing prevalence of infertility and hypogonadism, changing lifestyles, and increased awareness regarding infertility treatment to propel market demand

The rising prevalence of infertility and hypogonadism, changing lifestyles, and improved knowledge about infertility therapy are all contributing to the expansion of the human chorionic gonadotropin (HCG) industry. Hypogonadism, for example, is defined by low serum the hormone testosterone concentration, which is followed by an array of clinical features such as poor morning erections, ED, memory loss, low libido, physical decline in health and power, difficulty concentrating, and depression. According to research published in July 2021 by BMC Endocrine Disorders, erectile dysfunction would affect 72.2% of adults worldwide in 2021.

Human Chorionic Gonadotropin (hCG) Market- Key Insights

As per the analysis shared by our research analyst, the global Human Chorionic Gonadotropin (hCG) market is estimated to grow annually at a CAGR of around 6.48% over the forecast period (2023-2030)

The Human Chorionic Gonadotropin (hCG) industry is projected to grow at a significant rate due to the increasing prevalence of infertility and hypogonadism, changing lifestyles, and increased awareness regarding infertility treatment

Based on Technology segmentation, natural source extraction was predicted to show maximum market share in the year 2022

Based on Therapeutic Area segmentation, Female Infertility Treatment was the leading Technology in 2022

Based on end user segmentation, Fertility Clinics was the leading Technology in 2022

On the basis of region, North America was the leading revenue generator in 2022

Human Chorionic Gonadotropin (hCG) Market- Segmentation Analysis:

The Global Human Chorionic Gonadotropin (hCG) Market is segmented on the basis of Technology, Therapeutic Area, End User, and Region.

The market is divided into categories based on product Technology: Recombinant Technology and Natural Source Extraction. The natural source extraction segment dominated the worldwide market and is likely to continue to do so during the forecast period. The leading competitors in the hCG sector have a high demand for gonadotropins derived from natural sources, which has been an important development in the market over the past few years and has contributed significantly to the income earned by this segment.

The market is divided into categories based on Therapeutic Area: Male Hypogonadism, Female Infertility Treatment, Oligospermia Treatment, and Others. Infertility is described as the couple's inability to become pregnant or the woman's inability to sustain a pregnancy to term. Because the human chorionic gonadotropin (HCG) hormone is important following embryo development during pregnancy, its usage in infertility therapy has gained popularity in both men and women. Female infertility can be caused by a variety of factors. Tubal abnormalities such as a uterine illness, blocked fallopian tube, follicular problems, polycystic ovarian syndrome (PCOS), various and endocrine system disorders are among the leading causes, according to the World Health Organization.

Human Chorionic Gonadotropin (hCG) Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. Over the projection period, North America is expected to experience considerable market growth. The rise can be linked to the region's well-established healthcare infrastructure, advantageous reimbursement regulations, and the rising burden of infertility.

Human Chorionic Gonadotropin (hCG) Market- Competitive Landscape:

Companies sell their products through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new product launches, distribution network development, R&D spending, and mergers and acquisitions. For instance, in June 2022, Inception Fertility extended its ecosystem with the introduction of HavenCryo, a long-term biological tissue and cryopreservation preservation solution that provides fertility professionals and patients with a one-of-a-kind experience.

Recent Developments:

In June 2022, with the introduction of HavenCryo, a long-term reproductive tissue and cryopreservation storage solution that provides a distinctive experience for fertility practitioners and patients, Inception Fertility extended its ecosystem.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET KEY PLAYERS

GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY

GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA

GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER

GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY REGION

Table of Contents

1. Human Chorionic Gonadotropin (hCG) Market Overview

2. Executive Summary

3. Human Chorionic Gonadotropin (hCG) Key Market Trends

4. Human Chorionic Gonadotropin (hCG) Industry Study

5. Human Chorionic Gonadotropin (hCG) Market: COVID-19 Impact Analysis

6. Human Chorionic Gonadotropin (hCG) Market Landscape

7. Human Chorionic Gonadotropin (hCG) Market - By Technology

8. Human Chorionic Gonadotropin (hCG) Market - By Therapeutic Area

9. Human Chorionic Gonadotropin (hCG) Market - By End User

10. Human Chorionic Gonadotropin (hCG) Market- By Geography

11. Key Vendor Analysis- Human Chorionic Gonadotropin (hCG) Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â